56results about "Cationic antimicrobial peptides" patented technology

The application discloses a kind of composition with immunoregulation and anti-aging function and preparation method thereof, and core component is marine collagen peptide, fusion polypeptide CPF-1, targeting senescent cell monoclonal antibody mAb Senolix, five gallate acyl glucose (PGG) and Hericium erinaceus polysaccharide.Fusion polypeptide CPF-1 is designed by domain fusion strategy, with collagen binding, immune activation and antibacterial function;Monoclonal antibody mAb Senolix targets the surface antigen p16^(INK4a) of senescent cell, and removes senescent cell by ADCC effect.The composition significantly improves immune cell activity, promotes collagen synthesis and reduces chronic inflammation through the synergistic effect of multiple components, and shows excellent immunoregulation and anti-aging effect in in vitro cell model and immunosuppressed mouse model, and can be used for developing immune enhancer, anti-aging drug or functional food.

The invention relates to an antimicrobial peptide consisting of the amino acid sequence: RX1WILX2WLRTWX3X4 wherein X1, X2, X3 and X4 are independently selected from K and R, and wherein each amino acid is independently in the L or D configuration, or a salt or solvate thereof. The use of said antimicrobial peptide in the treatment of an infection caused by Gram negative bacteria, Gram positive bacteria, fungi, and / or yeasts, as well as the use of said peptide as an antimicrobial agent for the prevention of contamination of an article or a living tissue by and / or for the decontamination of an article or a living tissue from Gram negative bacteria, Gram positive bacteria, fungi, and / or yeasts are further aspects of the invention.

The chimeric signal peptide for protein expression comprises an N region, a hydrophobic region, and a C region, wherein the N region and the C region are from the same signal peptide of a first protein, and the hydrophobic region is from the signal peptide of a second protein, and the first protein is different from the second protein. The first and second proteins can be independently selected from the group consisting of BM40, IL2, HA, insulin, CD33, IFNA2, IgGK leader, AZU, and SEAP.

Compositions are provided for the formulation of theta defensins and / or theta defensin analogs that are highly suitable for parenteral administration. Compositions are provided for the formulation of theta defensins and / or theta defensin analogs that are highly suitable for parenteral administration.SOLUTION: Such formulations provide the theta defensin and / or theta defensin analog in a slightly acidic buffer containing propylene glycol. Surprisingly, the inventors have found that such formulations increase the bioavailability of θ-defensins and / or θ-defensin analogues so provided by at least a factor of 10 compared to conventional isotonic saline solutions, and dramatically improve bioavailability in human subjects compared to animal models. The inventors have also found that such formulations advantageously exhibit low viscosity at high peptide concentrations, allowing reduced injection volumes and sterilization by simple filtration.SELECTED DRAWING: Figure 2

Peptides for use in systems that prevent the interaction of the FadA protein released from the Fusobacterium nucleatum (F. nucleatum) bacterium with E-cadherin, which has a carcinogenic effect, or the inhibition of the microorganism with antimicrobial agents and that will inhibit the carcinogenesis mechanisms of F. nucleatum infection and enable the development of therapeutic systems against infections that may occur due to the decreased immunity of patients undergoing cancer treatment with the use of peptides with anti-cancer and antimicrobial properties by developing ten peptides with FadA protein binding energy greater than −11.6 kcal / mol. Peptides with anticancer and antimicrobial properties allow the development of therapeutic systems to prevent F. nucleatum infection, to prevent cancer development after F. nucleatum infection, or to develop therapeutic systems against infections that occur due to the decreased immunity of cancer patients due to cancer treatment.

Described herein is a bifunctional peptide, compositions comprising the same, and methods useful for treatment of peri-implant disease.

The present invention describes a branched peptide of formula (I), the use of the same as an antibacterial, and related pharmaceutical compositions or medical devices.

To provide hepcidin analogs with improved in vivo half-lives, and related pharmaceutical compositions and methods of use thereof.SOLUTION: The present invention relates generally to hepcidin analog peptides and methods of making and using the same. In certain embodiments, hepcidin analogs exhibit one or more hepcidin activities. In certain embodiments, the present invention is directed to hepcidin peptide analogs comprising one or more peptide subunits, wherein the peptide subunits form a cyclized structure via an intramolecular bond, e.g., an intramolecular disulfide bond. In certain embodiments, cyclized structures have increased potency and selectivity compared to non-cyclized hepcidin peptides and analogs thereof. In certain embodiments, the hepcidin analog peptides of the present invention exhibit an extended half-life compared to hepcidin or conventional hepcidin analogs when delivered orally.SELECTED DRAWING: None

Disclosed is an antimicrobial peptide comprising the sequence IGKX1FX2RIVX3RKX4RFLX5X6LVRPLX7 (SEQ ID NO: 7), wherein each of X1, X2, X3, X4, X5, X6, and X7 is an amino acid independently selected from the group consisting of E, K, R, L, I, V, F, A, W, V and P, preferably from the group consisting of E, K, R, L, I, V, F, A, W and V, more preferably from the group consisting of E, K, R, L, W and V. Optionally, one amino acid in this sequence selected from the group of L, V, F, A, I, W, Y or Q, with the exception of X1-X7, is replaced by another amino acid selected from said group or by P. Particularly preferred peptides are IGKEFKRIVERKWRFLRELVRPLR (SEQ ID NO: 2), IGKKFKRIVRRKKRFLRKLVRPLR (SEQ ID NO: 3), IGKEFKRIVERKWRFLRKLVRPLR (SEQ ID NO: 4), IGKEFLRIVERKWRFLRKLVRPLL (SEQ ID NO: 5) and IGKEFLRIVERKWRFLVKLVRPLL (SEQ ID NO: 6).

The present invention provides hepcidin analogs with improved in vivo half-lives, as well as related pharmaceutical compositions and methods of use. The present invention generally relates to hepcidin analog peptides and methods of making and using them. In certain embodiments, the hepcidin analogs exhibit one or more hepcidin activities. In certain embodiments, the present invention relates to hepcidin peptide analogs comprising one or more peptide subunits, which form a cyclized structure via an intramolecular bond, such as an intramolecular disulfide bond. In certain embodiments, the cyclized structure exhibits increased potency and selectivity compared to non-cyclized hepcidin peptides and analogs thereof. In certain embodiments, the hepcidin analog peptides of the present invention exhibit an extended half-life when delivered orally compared to hepcidin or conventional hepcidin analogs.

The present invention relates to the fragment-based synthesis of peptides, in particular the peptide LL37. In specific the present invention relates to a method for fragmented solid phase synthesis of an LL37 peptide of SEQ ID NO: 1, or a variant thereof, comprising providing a first fragment of LL37, or a variant thereof, coupled to a first resin solid support by a cleavable linker, providing at least one further side chain protected fragment of LL37 coupled to a second resin solid support, wherein the fragment-resin linker is acid labile, cleaving the further side chain protected fragment(s) from the second solid support without deprotecting the side chains, and sequentially coupling the first and further fragments to produce a peptide of SEQ ID NO: 1, or a variant thereof.

Disclosed herein are PEG-maximin H5 peptide conjugates and methods for using the same in the treatment or prevention of biofilms and biofouling.

An isolated, non-naturally occurring cell penetrating peptide (CPP) comprising the amino acid sequence: RRSRTARAGRPGRNSSRPSAPR [SEQ ID NO: 1] and sequences having at least 60% similarity to SEQ ID NO: 1.

The present invention relates to peptides for treatment of skin diseases and skin conditions. In particular, the present invention relates to peptide for treatment of wounds and / or blisters in patients suffering from a skin disease or skin condition selected from the group consisting of blistering disease, a disease or condition characterized by excessive wound exudate, a disease or condition characterised by a dysregulated skin microbiome and scars.

The invention relates to a peptide that can be used as an alternative to existing antibiotics for the inhibition of pathogenic microorganisms and the treatment of infections due to these microorganisms, contributing to the prevention of resistance development arising from antibiotic use by reducing antibiotic use, is safer compared to human-derived natural peptides, has a very low toxicity compared to existing antimicrobial peptides, and also reducing tissue damage and side effects during infection by reducing inflammation due to microbial infections, also having the potential to regulate the immune system and immunomodulation, which will contribute to fight infections by influencing the activation and function of immune cells.

The application discloses a pig beta-defensin-3 gene core promoter and a construction method and application thereof, and belongs to the technical field of genetic engineering. The sequence of the core promoter is shown as SEQ ID No. 1, the core promoter has significant promoter activity in pig small intestinal epithelial cells, and can be regulated by nutrients such as sodium butyrate and glutamine. The application also discloses a construction method for specifically amplifying the core promoter, which comprises the following steps: performing PCR amplification by taking pig small intestinal epithelial cell DNA as a template, taking the upstream primer and the downstream primer shown as SEQ No. 2-SEQ No. 3 as the primer, constructing a pMD-18T-pBD-3-P recombinant plasmid, and taking the recombinant plasmid as a template to amplify a core promoter fragment. The core promoter provides an excellent experimental system for studying the transcriptional regulation mechanism of the pig beta-defensin-3 gene, the nutrient response characteristics provide a new platform for studying the interaction between nutrition and immunity, and the core promoter has a wide application prospect in the field of healthy breeding of livestock and poultry.

A method for producing a SARS-CoV-2 virus-like particle-based protein subunit vaccine. The method comprises creating a fusion protein by combining a DNA sequence encoding an iLOV protein with a DNA sequence encoding a peptide linker and a cleavage site for enterokinase protease and a DNA sequence encoding a Receptor Binding Domain (RBD) of the SARS-CoV-2 viral spike protein. The RBD protein is attached to a “Spy Tag” peptide. The peptide linker cleavage site DNA sequence is between the iLOV protein DNA sequence and either the SARS-CoV-2 viral protein DNA sequence or the “Spy Tag” peptide DNA sequence. The DNA sequence encoding the fusion protein is introduced into a P. pastoris host to form transformants. At least one optimal recombinant is identified from the transformants using fluorescence to detect optimal expression levels of the SARS-CoV-2 viral protein. The SARS-CoV-2 viral protein is isolated from the fusion protein by cleaving the iLOV protein and linker sequences from the target protein. The RBD sequence can be mutated to represent RBD variants or homologous sequences or improve expression and alter its glycosylation pattern. The RBD sequence can belong to any virus within the coronavirus family.

The present application provides a tuberculosis vaccine based on bovine beta defensin 5 and its application in preventing tuberculosis, which comprises a fusion protein of tuberculosis AH antigen and bovine beta defensin 5 or a coding sequence thereof. The present application fuses and expresses Ag85A and HspX, which are surface dominant antigens of Mycobacterium tuberculosis, and an optimized sequence of bovine beta defensin 5, and then purifies the protein to mix with poly I:C to prepare a fusion protein vaccine AHB-P. Or the coding sequence of the fusion gene is optimized and then connected to a vector pVAX1 to prepare a fusion DNA vaccine pVAX1-AHB. The respiratory mucosa of mice is immunized with the two fusion vaccines, and it is proved that the two fusion vaccines can enhance the body's resistance to tuberculosis infection.

The present invention provides a covalent conjugate. The conjugate includes an antibody or antibody derivative, at least two LL37-derived polypeptides, and a payload. The antibody or antibody derivative targets a cell that has phosphatidylserine in its outer leaflet. The payload includes: a small molecule cytotoxic drug of less than 3 kDa, or a plurality thereof; or a peptide or protein of less than 100 kDa. Uses and methods of using these covalent conjugates are also provided, related to enhancing delivery of the antibody / derivative or the payload, e.g. to enhance therapeutic or diagnostic effectiveness.

Described is an antibacterial protein S2200 which has specific antibacterial activity against Staphylococci including Staphylococcus aureus. More specifically, described is antibacterial protein S2200 specific for Staphylococci including Staphylococcus aureus, which has the ability to specifically lyse Staphylococci including Staphylococcus aureus and has the amino acid sequence represented by SEQ ID NO: 1; and a pharmaceutical composition for the treatment of infections caused by Staphylococci including Staphylococcus aureus, containing as an active ingredient antibacterial protein S2200 specific for Staphylococci including Staphylococcus aureus.

The present disclosure relates to RNA and other polynucleotides encoding antigens, which can be used in vaccine compositions. In some examples, the RNA or polynucleotides further encode an adjuvant, such as a cathelicidin or fragment thereof. The present disclosure also relates to the use of the RNA, polynucleotides, or compositions in methods of inducing an immune response in a subject.

The present application relates to the technical field of biotechnology, and particularly relates to an antibacterial and anti-inflammatory dual-activity polypeptide and application thereof.The amino acid sequence of the dual-activity polypeptide is shown as SEQ ID NO.1.The dual-activity polypeptide has good biocompatibility, can inhibit the growth of periodontitis pathogenic bacteria such as Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans, inhibit the formation of bacterial biofilm, has high biological safety and no cytotoxicity, and can avoid bacterial drug resistance.The polypeptide can also prevent and treat periodontitis by reversing the phenotype of inflammatory cells and inhibiting the release of pro-inflammatory cytokines.Animal experiments show that the dual-activity polypeptide can effectively prevent and treat periodontitis, has great application value in the field of periodontitis treatment, and can also be used for the treatment of related bacterial flora infectious diseases and as a surface coating of implantable devices.

The present invention provides novel kinocidin peptides comprising a C-terminal portion of a kinocidin, wherein the C-terminal portion encompasses an α-helical secondary structure and further displays antimicrobial activity. The kinocidin peptides of the invention are derived from and correspond to a C-terminal portion of a kinocidin that includes a γκO core and that can be a CXC, CC, or C class chemokine. Structural, physicochemical and functional properties of this novel class of antimicrobial peptides and amino acid sequences of particular kinocidin peptides are also disclosed. The invention also provides related antimicrobial methods.

Antimicrobial defensin peptide variants comprising modified C-terminal fragments of a defensin and nucleic acids encoding the same are disclosed. Compositions comprising the defensin variant peptides and methods of their use to control microbial infections of plants and vertebrate subjects as well as contamination of feedstuffs and foodstuffs are also disclosed.

The present invention relates to nanostructured proteins, more particularly to fusion proteins suitable for their selective delivery to specific cell and tissue types. It also relates to nanoparticles comprising such nanostructured proteins, as well as nucleic acids, vectors, cells comprising said proteins, and therapeutic uses thereof.

This disclosure relates to antigen-encoding RNAs and other polynucleotides that can be used in vaccine compositions. In some examples, the RNA or polynucleotide also encodes an adjuvant, such as cathelicidine or a fragment thereof. This disclosure also relates to the use of RNA, polynucleotides, or compositions in methods for inducing an immune response in a subject.

Antimicrobial SbDef1-type peptides and proteins are disclosed along with compositions comprising the SbDef1-type peptides and proteins and transgenic or genetically edited plants or microorganisms that express the SbDef1-type peptides and proteins to inhibit growth of pathogenic microbes. Such SbDef1-type peptides and proteins, compositions, plants, and microorganisms can provide for inhibition of microbial growth.

Computational systems and methods are described for identifying new α-helical antimicrobial peptides using a systemic consensus formula. Newly identified α-helical antimicrobial peptides are tested experimentally and show potent microbiocidal activities.

The invention discloses a feed additive for antibiotic-free breeding as well as a preparation method and application of the feed additive. The additive takes dual-vector co-expression recombinant lactococcus lactis engineering bacteria as a core and is supplemented by microencapsulated functional small molecules. The recombinant engineering bacterium can synchronously express the fusion polypeptide and a single-chain antibody fragment, wherein the fusion polypeptide contains an N-terminal antibacterial functional domain, a flexible linker and a C-terminal immune enhancement functional domain, and antibacterial-immune synergy is realized; the single-chain antibody fragment aims at escherichia coli F18 adhesin and can specifically block pathogenic bacterium colonization. During preparation, the recombinant engineering bacteria are firstly prepared into freeze-dried powder, and then the freeze-dried powder is compounded with the microencapsulated functional micromolecules in proportion. Experiments show that the additive can remarkably improve the growth performance of weaned piglets, reduce the diarrhea rate, enhance the immune function and improve intestinal health, the effect of the additive is better than that of traditional antibiotics and a scheme of directly adding functional components, and efficient, safe and sustainable technical support is provided for antibiotic-free breeding.

Provided are compositions and methods employing antimicrobial root nodule specific cysteine-rich (NCR) peptides and variants thereof, including folded variants of NCR peptides (NCRPFV), including folded variants of antimicrobial NCR peptides and proteins (NCRPFV) that exhibit advantageous antifungal properties and desirable resistance or sensitivity to protease cleavage, the antimicrobial NCRPFV may be applied directly ex vivo to a plant, human or animal, or may be applied in vivo to a plant, human or animal.